
MASH
Latest Content
Latest Videos
Shorts

More News

A systematic review and meta-analysis found GLP-1 RAs improved liver and metabolic markers in MASLD and MASH, but long-term benefits remain unproven.

Two machine learning models identifies MASLD in lean adults using 8 routine clinical measurements.

A higher PNR is associated with lower odds of MASLD and advanced liver fibrosis, but further studies are needed to validate findings.

Proinflammatory diets were tied to higher mortality in MASLD and MetALD, whereas antioxidant-rich diets tracked with better survival.

Lean MASLD shows milder histology than overweight and obese MASLD but similar mortality and event risk, with fibrosis tied to prognosis.

A meta-analysis of 22 studies found steatotic liver disease in about three-quarters of patients with sleep-disordered breathing.

A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.

Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.

A national study found comorbidities may drive worse long-term survival among patients with MASH awaiting or undergoing liver transplant.

MASLD was linked to higher odds of EoE and reflux-related diseases, suggesting metabolic dysfunction may contribute to esophageal disease.

MASLD/MASH was associated with higher mild cognitive impairment risk and lower dementia odds, but competing risks may explain the latter finding.

A recent study found semaglutide more than doubled the likelihood of MASH resolution, but it did not significantly improve fibrosis.

AI phenotyping identified cardiovascular and kidney disease as key predictors of rapid fibrosis progression, complications, and higher costs in MASH.

Real-world data show patients with MASH reach cirrhosis in just 16 months, fueling calls for wider use of fibrosis biomarkers like FIB-4.

Naim Alkhouri, MD, discusses real-world resmetirom data in MASH, GLP-1 combinations, and using ANTICIPATE-NASH in practice.

Resmetirom boosts MASH cardiovascular protection, lowering LDL cholesterol and Lp(a) even on statins, and pushes routine Lp(a) testing.

Simple FNI labs pinpoint high‑mortality MASLD fibrosis in type 2 diabetes, challenging FIB‑4 and sharpening MASH liver disease screening.

MASH cirrhosis carries high risks of death, decompensation, and liver cancer—especially with type 2 diabetes—while predictive tools remain limited.

Many MASH cirrhosis trials use histologic endpoints, but a new review finds limited standardization of these outcomes across studies.

Evidence suggests new therapies like GLP-1 receptor agonists, initially approved to treat obesity and diabetes, can also benefit patients with liver disease.

MASH can have a significant impact on patients’ quality of life, particularly if they have comorbidities or advanced fibrosis.












